To validate this hypothesis, we performed tumor challenge experiments by systemically depleting CCR2+ monocytes, using the monoclonal antibody MC-21 [34], or by blocking the egress of monocytes from the bone marrow towards inflammatory sites taking advantage of CCR2-deficient mice [35], under SULT2B1b manipulation. Here, CCR2 is linked to neoplasm.